Adenylate Cyclase Toxoid-211
Recombinant Adenylate Cyclase Toxoid was expressed in B. pertussis.
Adenylate cyclase toxin (ACT) is an important virulence factor secreted by Bordetella pertussis. When a lung infection is underway, ACT interacts with tracheal epithelial cells, inserting itself into cytoplasmic membranes, aiding the adhesion of bacteria to the airway lining. Host phagocytes responding to the site of infection are disabled by cAMP generated by ACT. Encoded by the Bordetella pertussis cyaA gene, adenylate cyclase toxin is single 1706 amino acid polypeptide, with an apparent molecular weight of 220 kDa. The N-terminal of this protein contains an adenylate cyclase domain which binds to host cell calmodulin and catalyzes unregulated conversion of cellular ATP to cAMP. The C-terminal, receptor binding domain, contains numerous repeat in toxin (RTX) motifs and is responsible for binding to the cellular receptor on the surface of immune cells, translocation to the cell cytosol and creating cation-selective pores in the host cell membrane.
Each vial contains 50 ug of Adenylate Cyclase Toxoid, recombiant in 50 ul of 0.05M Tris, 8M Urea, 0.002M EDTA, PH 8.0.
The endotoxin content, determined using a kinetic chromagenic LAL assay, is <20 EU/mg.
This product is supplied as an aseptically packaged liquld, frozen. Aliquots, sized for single use, may be frozen at -20 centigrade to avoid repeated thawing and freezing of sample.
Good laboratory technique should be employed in the safe handling of this product. Wear appropriate laboratory attire including a lab coat, gloves and safety glasses. Nitrile gloves are recommended when handling lyophilized material. This product is intended for research purposes by qualified personnel only. It is not intended for use in humans or as a diagnostic agent.